PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...
This methodology had been discussed with an International Monetary Fund (IMF) expert, under the technical assistance mission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback